Medical experts discuss the financial impact of early detection in colorectal cancer.
Ryan Haumschild, PharmD, MS, MBA, emphasizes the importance of early detection, tailored interventions, and the associated costs in treating colorectal cancer. He highlights the financial burdens on patients, health care systems, and payers, pointing out the expenses linked to hospitalizations, surgeries, and long-term treatment.
David Fenstermacher, PhD, delves into the economic impact of metastatic colorectal cancer. He mentions that in 2020, approximately $22 billion was spent on colorectal cancer care, making it the second most costly cancer type after female breast cancer. Dr Fenstermacher emphasizes the need to reduce financial toxicity and discusses the high costs of biomarker testing, genetics analysis, and the overall economic burden on both insured and uninsured patients.
Ben George, MD, highlights the importance of early detection and prevention, emphasizing that if patients receive a diagnosis of cancer at a late stage, it results in significant financial and systemic toxicity. Early detection in stages 1 and 2 can lead to a 90% cure rate, underlining the value of identifying high-risk individuals through genetic risk scores.
John L. Marshall, MD, offers a controversial perspective on screening. He argues that the current screening methods are invasive, expensive, and lack the high sensitivity and specificity required for early detection. Dr Marshall questions whether the increased incidence of colorectal cancer from these screenings ultimately leads to more cures, and he calls for a more cost-effective and noninvasive approach to screening.
The discussion revolves around the challenges of early detection and the financial burdens associated with colorectal cancer care, with a focus on seeking innovative ways to enhance screening, reduce financial toxicity, and improve outcomes for patients.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More